JSSX 2026 | Meet Medicilon in Tsukuba: Advancing DMPK and ADMET Research from Discovery to IND
The 41st Annual Meeting of the Japanese Society for the Study of Xenobiotics (JSSX 2026) will be held from November 16-19, 2026, at the Tsukuba International Congress Center in Japan.
Under the theme “Shu-Ha-Ri/In-On-Out: New Paradigm in ADMET Sciences Pioneering the Unknown Path of the Future,” the annual meeting will bring together researchers, pharmaceutical professionals, and industry experts to exchange insights on the latest advances in drug metabolism, pharmacokinetics, bioanalysis, drug safety, and ADMET sciences.
- Date: November 16-19, 2026
- Venue: Tsukuba International Congress Center, Tsukuba, Japan
- Event: The 41st Annual Meeting of JSSX
- Medicilon Booth: #51
Meet Medicilon at JSSX 2026
Medicilon will participate in JSSX 2026, bringing its expertise in Drug Metabolism and Pharmacokinetics (DMPK) and integrated preclinical R&D services to connect with pharmaceutical and biotechnology professionals.
As a full-service preclinical CRO, Medicilon provides comprehensive support across drug discovery, pharmaceutical research, and preclinical development, helping innovative drug developers advance their programs from Target to IND.
Comprehensive DMPK Services to Support Drug Development
Medicilon offers integrated DMPK solutions for small molecules, biologics, and emerging therapeutic modalities, covering key aspects of drug metabolism, pharmacokinetics, and bioanalysis.
Key DMPK Capabilities Include:
- Drug Metabolism: In vitro and in vivo metabolism studies, metabolic stability, metabolite identification, and metabolic pathway characterization.
- Pharmacokinetics (PK): Pharmacokinetic studies, tissue distribution, excretion, and PK evaluation across different animal models.
- Bioanalysis: Quantitative bioanalytical methods and sample analysis to support pharmacokinetic and toxicokinetic studies.
- Drug-Drug Interaction (DDI): Evaluation of drug-metabolizing enzymes and transporters, supporting drug interaction risk assessment.
- New Modalities: DMPK research and analytical support for biologics and emerging therapeutic modalities.
Through integrated DMPK capabilities and cross-functional collaboration, Medicilon helps clients generate reliable data to support drug candidate selection, preclinical development, and IND-enabling studies.
Meet Our Team On Site
Dr. Pin Jiang, Ph.D. – Vice President of DMPK, Medicilon
Dr. Jiang leads Medicilon’s DMPK research and development activities, with expertise in DMPK studies for small molecules, biologics, and emerging therapeutic modalities. He holds a Ph.D. from China Pharmaceutical University and completed his postdoctoral research at Fudan University.
Mr. Junhong Xu -Vice President of Business Development, Medicilon
With extensive experience in preclinical CRO business development and client partnerships, Mr. Xu will connect with industry partners to explore collaboration opportunities and discuss their drug development needs.
Our team looks forward to engaging with pharmaceutical companies, biotechnology innovators, and research professionals to exchange insights on DMPK strategies, ADMET research, and preclinical drug development.
Beyond DMPK -Your Integrated Preclinical CRO Partner
Beyond DMPK, Medicilon provides integrated services spanning drug discovery, medicinal chemistry, biology, pharmaceutical development, toxicology, and regulatory support.
With experience supporting more than 690 IND approvals and over 20 overseas licensing deals for innovative drugs, Medicilon is committed to delivering comprehensive preclinical R&D solutions and helping clients navigate the journey from Target to IND.
Connect with Medicilon in Tsukuba
JSSX 2026 provides an excellent opportunity to exchange scientific insights and explore new collaborations in DMPK and ADMET research.
We look forward to meeting you in Tsukuba! Visit Medicilon at Booth #51 to connect with our team and discuss how our integrated DMPK and preclinical R&D capabilities can support your drug development programs.
Let’s connect at JSSX 2026 and advance innovative drug development together!
